Vero Biotech: Secures $50M in Funding

  • Vero Biotech LLC, an Atlanta, Georgia-based biotechnology company, closed a senior secured term loan of $50m
  • Runway Growth Capital provided the financing
  • Vero Biotech (formerly known as GeNO LLC), a biotechnology company focused on the design, development, and commercialization of next-generation products
  • The company also developed the GENOSYL® Delivery System (GENOSYL DS), a inhaled nitric oxide delivery system approved by the U.S. Food and Drug Administration (FDA)
  • The GENOSYL DS transforms the delivery and use of nitric oxide, a vasodilator proven to play a critical role in the care of patients with adult respiratory distress syndrome
  • The GENOSYL® Delivery System authorized by the U.S. FDA for expanded emergency use access for patients with cardiopulmonary complications
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

US FTC Reports Consumers Lost $15.9 Billion to Fraud in 2025

The FTC reveals alarming fraud losses impacting millions of Americans.Highlights: Consumers lost $15.9 billion to fraud in 2025,...

EU, UK, and Switzerland Strengthen T1 Testing Plan for 2027 Transition

Three regions collaborate on testing ahead of joint financial move.Highlights: EU, UK, and Switzerland announce T1 testing plan.Collaboration...

NextGen FinCrime Initiative Strengthens Cross-Sector Collaboration

New talks aim to enhance cooperation in tackling financial crime across industries.Highlights: NextGen FinCrime initiative aims to unite...

Aviva Launches Insurance App on ChatGPT, Enhancing Customer Interactions

The new app aims to simplify insurance queries and support for users.Highlights: Aviva introduces an insurance app on...